This site uses cookies to enhance your browsing experience. By continuing navigation, you agree to the use of cookies. For more information about our use of cookies, see our Privacy Policy.
Enable proactive heart failure management by providing data-driven patient management solutions in the home that detect worsening heart failure earlier and help inform ongoing therapeutic interventions.
Strengthen relationships and efficiencies with easy-to-use tools that connect patients, clinicians and reimbursement teams through streamlined patient management driving meaningful clinical and economic outcomes.
Improve the quality of life for all members of the heart failure care community, including patients, caregivers and clinicians.
Anthony Nunez, MD, a cardiothoracic surgeon, and Harry Rowland, PhD, a mechanical engineer, met in February 2007. They were inspired to start the company after witnessing family members suffer from heart failure (HF). They realized they were uniquely qualified to invent a more effective solution to improve the quality of life for HF sufferers, their loved ones, and caregivers. Harry assembled a core team, including Olivia Nichols and Michael Nagy, to develop the technology, and together they have built the company over the past decade.
Anthony and Harry met in Peoria, Illinois
Anthony and Harry founded Endotronix
Worked with collaborators formerly of Bradley University and Caterpillar to make a breakthrough innovation, a new technology that passively reads wireless sensors
Completed licensing for two patents from NASA for ultra-miniature wireless sensor designs
Received a $3 million investment from Luxemburg Capital, founded by successful healthcare entrepreneur James Hummer, to expand development efforts
Accomplished the first in vivo demonstration of its wireless sensor reader technology at Cleveland Clinic’s Lerner Research Institute
The Central Illinois Angels from Peoria, IL and JumpStart Ventures from Cleveland, OH became investors
Built a prototype reader the size of a smart phone, showing the potential for patient friendly readings from the implantable pressure sensor
Demonstrated proof-of-concept for the catheter-based delivery system in an acute in-vivo model
Developed a novel sensor platform for implantable wireless electronics
Established corporate headquarters in Chicago, IL
Demonstrated an enhanced catheter-based delivery system that allowed for improved clinician control and visualization during sensor implantation for the first time in vivo
Completed a comprehensive in-vivo study of the 1st generation sensor system
Introduced the CordellaTM System, a comprehensive solution for heart failure management
First patient use of the myCordella™ system as part of the clinical development program
Moved to 16,000+ sqft facility in Lisle, IL
Implanted 50 Cordella™ sensors worldwide
Over 200 patients on the Cordella HF System
Implanted 300th Cordella Sensor worldwide
Implanted 500th Cordella Sensor worldwide
Edwards LIfesciences acquires Endotronix
Edwards LIfesciences acquires Endotronix
Implanted 500th Cordella Sensor worldwide
Implanted 300th Cordella Sensor worldwide
Over 200 patients on the Cordella HF System
Implanted 50 Cordella™ sensors worldwide
Moved to 16,000+ sqft facility in Lisle, IL
First patient use of the myCordella™ system as part of the clinical development program
Introduced the CordellaTM System, a comprehensive solution for heart failure management
Closed a $32M Series C Financing round with a world class investor group to support clinical development and commercialization activities
Completed a comprehensive in-vivo study of the 1st generation sensor system
Demonstrated an enhanced catheter-based delivery system that allowed for improved clinician control and visualization during sensor implantation for the first time in vivo
Established corporate headquarters in Chicago, IL
Developed a novel sensor platform for implantable wireless electronics
Demonstrated proof-of-concept for the catheter-based delivery system in an acute in-vivo model
Built a prototype reader the size of a smart phone, showing the potential for patient friendly readings from the implantable pressure sensor
The Central Illinois Angels from Peoria, IL and JumpStart Ventures from Cleveland, OH became investors
Accomplished the first in vivo demonstration of its wireless sensor reader technology at Cleveland Clinic’s Lerner Research Institute
Received a $3 million investment from Luxemburg Capital, founded by successful healthcare entrepreneur James Hummer, to expand development efforts
Completed licensing for two patents from NASA for ultra-miniature wireless sensor designs
Worked with collaborators formerly of Bradley University and Caterpillar to make a breakthrough innovation, a new technology that passively reads wireless sensors
Anthony and Harry founded Endotronix
Anthony and Harry met in Peoria, Illinois
Harry D. Rowland is co-founder and CEO of Endotronix. Dr. Rowland has led the company’s operations, strategy, and technology development since inception. His vision has been integral in raising $100M in VC and strategic financing and building the company to 70+ people. He received his PhD in mechanical engineering from the Georgia Institute of Technology, a BS in mechanical engineering, and a MA in economics from the University of California, Santa Barbara. Dr. Rowland has authored or presented numerous conference and journal papers in internationally recognized peer-reviewed publications such as Science and Nano, with his work referenced in nearly 500 scholarly articles. He has more than 15 issued patents and several pending applications.
Mike Dilworth is a seasoned manufacturing and operations executive in the healthcare industry. Most recently, Mr. Dilworth was Senior VP of Manufacturing Operations at Nanosphere (acquired by Luminex Corporation in 2016). Prior to that he held VP of Manufacturing roles at Plasma Surgical, Abbott Nutrition, and Ciba Vision Corporation. Throughout his career, Mr. Dilworth has demonstrated leadership in building winning teams as well as formulating and executing strategic plans. He has a proven ability to increase sales and profit by working with R&D and Marketing organizations to bring new products and processes to the market.
Mr. Dilworth holds a Bachelor of Science degree in Industrial Management from Georgia Southern College.
Angad Singh brings to Endotronix over 20 years of technology development and product leadership experience in the commercialization of ground-breaking medical products with a strong focus in the cardiovascular market. He served as Vice President of Engineering and Operations at CardioMEMS (now part of Abbott Laboratories), the first company to commercialize implantable wireless sensors for disease monitoring. Mr. Singh’s technical expertise and leadership were crucial in the transition of their Aortic Abdominal Aneurysm (AAA) and Heart Failure (HF) monitoring products from concept to commercialization and revenues in excess of $100M. More recently, Mr. Singh co-founded Polaris Surgical (now part of MiRus), where he led the development and commercialization of next generation surgical guidance systems and smart instrumentation to improve orthopedic and spine surgeries including the award-winning GALILEO™ Spinal Alignment Monitoring System, a first-of-a-kind real-time measurement and monitoring system. Prior positions include co-founder and Chief Technology Officer at Microgen Systems, Staff Engineer at SONY, and R&D Engineer at the Berkeley Sensor and Actuator Center. Mr. Singh has an M.S. degree in Electrical Engineering and Applied Physics from Case Western Reserve University and a B.S. degree in Electrical Engineering from the Visvesvaraya National Institute of Technology, India.
An established Quality and Regulatory medtech leader, Lisbert (Lis) Avila-Yu brings over 20 years of experience to Endotronix with a focus in new product development of implantable medical devices. Her extensive cardiovascular experience includes senior leadership roles in regulatory compliance and technical review at the British Standards Institute (BSI) and HeartWare (acquired by Medtronic in 2016). As Associate Director of Regulatory at HeartWare, she co-led regulatory efforts to obtain premarket approval (PMA) for a novel vascular assist device (VAD) and secured clinical trial approvals for products in the R&D pipeline. In addition, Ms. Avila-Yu has held multiple quality assurance roles at Cordis Corporation (previously a Johnson and Johnson company) focused on design reliability, process robustness, and quality management system optimization.
Ms. Avila-Yu holds an M.S. degree in Engineering Management and an MBA from Florida International University as well as a B.S. degree in Biomedical & Electrical Engineering from Duke University. Her professional credentials include the RAPS U.S. and European Regulatory Affairs Certifications and ASQ Certified Quality Engineering and Certified Quality Auditor.
Mike Culen is a seasoned sales leader with nearly two decades of experience in the medical industry. He brings a wealth of knowledge and expertise to Endotronix, leveraging his proven track record of building and managing high-performing sales organizations.
In his previous role as Vice President of Sales at Tulavi Therapeutics, an Incept company, Mike was instrumental in developing and executing sales and commercial strategies that drove success. Prior to Tulavi, he held sales leadership positions across various Incept companies including serving as Head of Sales at Imperative Care for 6 years and Head of Sales and Marketing at Ostial Corporation. Mike also held progressing sales leadership roles at Access Closure, culminating with Regional Sales Director, and was instrumental during the acquisition by Cardinal Health for $320M. Laying a foundation for his career, he began his journey in at Eli Lily in the Cardio and Neuroscience Divisions. Mike holds a bachelor’s degree from Eastern Mennonite University.
A seasoned medtech clinical operations leader, Andrea Sauerland brings over 30 years of clinical experience to her role. Prior to Endotronix, she held senior leadership roles at Novocure (Global Sr. Director of Clinical Trials) and HeartWare, Inc (Senior Director of Clinical Operations), where she oversaw global clinical operations for trials that lead to regulatory approval in the U.S. and Europe. Prior to that, Andrea held several roles culminating with Senior Project Director at INC Research (now owned by Syneos Health) where she supervised phase II and III clinical trials with over 3,000 patients across up to 200 sites in Europe, North America, India and Latin America. In addition, she predominately worked with cardiovascular companies during her time at Hesperion, a former CRO in Switzerland. Prior to joining the pharmaceutical and medtech industry, Andrea spent 4 years as a research nurse and study coordinator at the surgical intensive care units at the University of Hospital Zurich. Andrea received her bachelor’s in ICU nursing from University Hospital Zurich.
Tom Tovello has over 15 years of Finance and Accounting experience with start-ups in the manufacturing, distribution, and life science industries. Prior to joining Endotronix, Mr. Tovello served as Vice President of Finance at Beavers Holdings, LLC, a family office managing and operating multiple manufacturing, distribution, and real estate entities across the U.S. In addition, he held several finance-related leadership roles at PACK Pharmaceuticals (acquired by Rising Pharmaceuticals), a generic pharmaceutical developer, distributor, and marketer. Mr. Tovello began his career in public accounting at Cohen Reznick, P.C. (formerly the Reznick Group). Mr. Tovello is a Certified Public Accountant, has a M.B.A. from Northern Illinois University, and a B.S. degree from Eastern Illinois University with a focus on Finance and Accounting.
Jim is a highly experienced commercial leader in medical devices with strong expertise in scaling companies, divisions and regions to achieve significant growth. Jim joins Endotronix from his second tenure at Medtronic as a result of the successful acquisition of HeartWare, where he served as Vice President of Marketing and Medical Education. Before his role at Medtronic/HeartWare Jim worked for a start-up heart failure cardiac assist company, CHF Solutions, as Vice President of Sales and Marketing. Previous experience during his first tenure at Medtronic include Vice President of Product Marketing Cardiac Rhythm Management in Minneapolis, Vice President of Asia based in Hong Kong and Field Director. Additionally, Jim has held various sales and marketing leadership roles at Boston Scientific, Genzyme/Sanofi, Unilever and Procter & Gamble.
Jim has a Business Degree from University of Delaware and a MBA from Northeastern University.
David Wesner has more than 23 years of Human Resources (HR) experience with multinational organizations and start-ups, primarily in the healthcare space. He specializes in companies going through significant growth and supporting the growth with strong HR practices. During his career, he has developed centers of excellence to handle all HR operations activity, built global competency-based talent management programs and designed and implemented enterprise wide HRIS systems including talent acquisition, performance, succession, compensation, development and LMS platforms. Mr. Wesner joins Endotronix with extensive senior level experience across several former employers including Melinta Therapeutics, Hospira, and Getinge Group.
Mr. Wesner holds a Bachelor of Arts degree from Messiah College and a Master’s degree in human resource development from Villanova University as well as several professional certifications in Pension and Asset Management, Training and Development and a Mini-MBA.
A respected expert in cardiovascular research, Omid Forouzan has broad experience with over 10 years in pulmonary hypertension, exercise hemodynamics, and devices in heart failure management. Dr. Forouzan was an early contributor to the development of the Cordella PA Sensor and led field clinical activities from the preclinical phase through the first-in-human trial (SIRONA), feasibility trial (SIRONA 2), and the pivotal PROACTIVE-HF trial. He received his PhD in Biomedical Engineering from the University of Wisconsin-Madison with a focus on exercise hemodynamics in pulmonary hypertension, a MS in Biomedical Engineering from Tulane University, and BS in Mechanical Engineering from Tehran Polytechnic. Dr. Forouzan has authored over 30 journal papers and has been well-referenced in the field of cardiovascular research.
A leader in healthcare, Ariel Johnson brings together a wealth of experience across investor relations, strategy and marketing as she rejoins the Endotronix team in the role of Vice President of Strategy and Investor Relations. Most recently, Ariel served as the Vice President of Advanced Research and Data Analytics at UnitedHealth Group Research & Development and was responsible for leading teams in determining and communicating investment strategies to drive innovation and paradigm shifts in healthcare. Prior to that she held marketing roles at Endotronix with escalating responsibility, culminating in Director of Marketing. Prior to that she was an Equity Research Analyst for Piper Jaffray (now Piper Sandler) in medical devices and large-cap pharma. Having worked as an equities analyst, Ariel provided sell-side research coverage of the small-, mid- and large-cap medical device and large-cap pharma sectors and formed lasting relationships with the medical device investment community. Dr. Johnson has a Ph.D. in Oral Biology from the University of Illinois at Chicago, a M.S. in Chemistry from the University of Minnesota and a B.S. and B.A. in Chemistry, Biology and Physiology from the University of Minnesota.
An experienced software leader, Brett Quas has over 25 years in medical device and application development. Mr. Quas has led the software teams of numerous successful healthcare start-
ups, including HomMed, LLC (acquired by Honeywell). Prior to Endotronix, he founded Connected Healthcare Solutions (CHS), a medical device consulting company helping global
organizations bring innovative devices to market. At CHS Mr. Quas assisted in the growth and acquisition of multiple companies including Watermark Medical (merged with SleepMed) and
eDevice (acquired by iHealth). Originally engaging with Endotronix through CHS, Mr. Quas eventually transitioned to a full-time role, culminating in Vice President of Software
Engineering. His previous experience also includes software engineering and management roles at several successful start-ups, Honeywell International, and Ernst & Young, LLP, where he
focused on software innovation and large-scale application deployments.
Mr. Quas holds a Bachelor of Science degree in Computer Science from Northern Illinois University.
At Endotronix, we believe COLLABORATION AND TRUST drive our success. Our highly entrepreneurial work environment encourages responsibility, teamwork and a genuine sense of comradery.
Learn more about what it is like to work at Endotronix.
Careers